The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Ozempic is traditionally used as a treatment for type 2 diabetes (T2DM) to help patients manage blood sugar levels. However, ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy, to shame. Let's look deeper into these ...

A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans. © 2024 Fortune Media IP Limited. All Rights ...

Demand for weight loss jabs continues to surge, particularly as the NHS began offering Wegovy in late 2023 and will start offering Mounjaro to patients in March 2025. They have also become ...

More and more people are taking weight loss injectables like Wegovy and Mounjaro — and though the drugs are gaining credibility when used properly, pharmacy experts are worried that not everyone ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

The HS family SUV is the latest MG to be given a major overhaul, with new styling, more space, and a smoother driving experience. Should you consider the top-of-the-range model? The previous MG HS ...